Non-curative Treatment of Patients with Oral Tongue Squamous-cell Carcinoma

Overview

Journal Eur Arch Otorhinolaryngol

Specialty Otorhinolaryngology

Date 2019 May 10

PMID 31069467

Citations 3

Authors

R Mroueh

A Haapaniemi

T Saarto

L Gronholm

R Grenman

T Salo

A A Makitie

Affiliations

Soon will be listed here.

Abstract

Purpose: Late-stage OTSCC is associated with poor overall survival (OS). Non-curative treatment approach aims to improve quality of life and prolong survival of patients deemed incurable. The purpose of this study was to investigate the used non-curative treatment modalities for OTSSC and patient survival.

Methods: All patients diagnosed with OTSCC and treated with non-curative intent at the HUS Helsinki University Hospital (Helsinki, Finland) during the 12-year period of 2005-2016 were included. Survival analysis after the non-curative treatment decision was conducted using the Kaplan-Meier method in this population-based study.

Results: Eighty-two patients were identified. A non-curative treatment decision was made at presentation without any previous treatment in 26 patients (7% of all patients diagnosed with OTSCC during the study period). Palliative radiotherapy was administered to 24% of all patients. The average survival time after the non-curative treatment decision was 3.7 months (median 2 and range 0-26).

Conclusions: Due to the short mean survival time after decision for treatment with non-curative intent, and the notable symptom burden in this patient population, a prompt initiation of all non-curative measures is warranted.

Citing Articles

Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p.

Wang Q, Han J, Xu P, Jian X, Huang X, Liu D Cancer Manag Res. 2021; 13:1831-1841.

PMID: 33654431 PMC: 7910113. DOI: 10.2147/CMAR.S298236.

Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 "QUAD shot" regimen for incurable head and neck cancer.

Toya R, Saito T, Yamaguchi K, Matsuyama T, Watakabe T, Matsumoto T Radiat Oncol. 2020; 15(1):123.

PMID: 32460865 PMC: 7251877. DOI: 10.1186/s13014-020-01548-w.

Early mortality after diagnosis of cancer of the head and neck - A population-based nationwide study.

Talani C, Makitie A, Beran M, Holmberg E, Laurell G, Farnebo L PLoS One. 2019; 14(10):e0223154.

PMID: 31577831 PMC: 6774523. DOI: 10.1371/journal.pone.0223154.

References

Caponigro F, Massa E, Manzione L, Rosati G, Biglietto M, De Lucia L . Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol. 2001; 12(2):199-202. DOI: 10.1023/a:1008322415335. View

Rahnemai-Azar A, Rahnemaiazar A, Naghshizadian R, Kurtz A, Farkas D . Percutaneous endoscopic gastrostomy: indications, technique, complications and management. World J Gastroenterol. 2014; 20(24):7739-51. PMC: 4069302. DOI: 10.3748/wjg.v20.i24.7739. View

Hakulinen T, Tryggvadottir L, Gislum M, Storm H, Bray F, Klint A . Trends in the survival of patients diagnosed with cancers of the lip, oral cavity, and pharynx in the Nordic countries 1964-2003 followed up to the end of 2006. Acta Oncol. 2010; 49(5):561-77. DOI: 10.3109/02841860903575307. View

Vermorken J, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M . Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357(17):1695-704. DOI: 10.1056/NEJMoa071028. View

Roland N, Bradley P . The role of surgery in the palliation of head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2014; 22(2):101-8. DOI: 10.1097/MOO.0000000000000031. View

Bruera E, Yennurajalingam S . Palliative care in advanced cancer patients: how and when?. Oncologist. 2012; 17(2):267-73. PMC: 3286176. DOI: 10.1634/theoncologist.2011-0219. View

Heinonen T, Loimu V, Saarilahti K, Saarto T, Makitie A . End-of-life care pathway of head and neck cancer patients: single-institution experience. Eur Arch Otorhinolaryngol. 2017; 275(2):545-551. DOI: 10.1007/s00405-017-4843-x. View

Lok B, Jiang G, Gutiontov S, Lanning R, Sridhara S, Sherman E . Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. Oral Oncol. 2015; 51(10):957-62. PMC: 4758812. DOI: 10.1016/j.oraloncology.2015.07.011. View

Osera S, Yano T, Odagaki T, Oono Y, Ikematsu H, Ohtsu A . Peritonitis related to percutaneous endoscopic gastrostomy using the direct method for cancer patients. Surg Endosc. 2014; 29(10):2941-6. DOI: 10.1007/s00464-014-4026-4. View

10.

Saito A, Landrum M, Neville B, Ayanian J, Earle C . The effect on survival of continuing chemotherapy to near death. BMC Palliat Care. 2011; 10:14. PMC: 3184269. DOI: 10.1186/1472-684X-10-14. View

11.

Barker H, Paget J, Khan A, Harrington K . The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015; 15(7):409-25. PMC: 4896389. DOI: 10.1038/nrc3958. View

12.

Iqbal M, Kelly C, Kovarik J, Goranov B, Shaikh G, Morgan D . Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review. Radiother Oncol. 2018; 126(3):558-567. DOI: 10.1016/j.radonc.2017.12.011. View

13.

Romesser P, Romanyshyn J, Schupak K, Setton J, Riaz N, Wolden S . Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. Cancer. 2012; 118(24):6072-8. PMC: 4969004. DOI: 10.1002/cncr.27633. View

14.

Kamisetty A, Mayland C, Jack B, Lowe D, Rogers S . Place and time of death in patients treated with palliative intent for oral cancer. Br J Oral Maxillofac Surg. 2014; 52(5):458-60. DOI: 10.1016/j.bjoms.2014.03.003. View

15.

da Silva S, Hier M, Mlynarek A, Kowalski L, Alaoui-Jamali M . Recurrent oral cancer: current and emerging therapeutic approaches. Front Pharmacol. 2012; 3:149. PMC: 3459356. DOI: 10.3389/fphar.2012.00149. View

16.

Furness S, Glenny A, Worthington H, Pavitt S, Oliver R, Clarkson J . Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev. 2011; (4):CD006386. DOI: 10.1002/14651858.CD006386.pub3. View

17.

Mroueh R, Haapaniemi A, Grenman R, Laranne J, Pukkila M, Almangush A . Improved outcomes with oral tongue squamous cell carcinoma in Finland. Head Neck. 2017; 39(7):1306-1312. DOI: 10.1002/hed.24744. View

18.

Cocks H, Ah-See K, Capel M, Taylor P . Palliative and supportive care in head and neck cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016; 130(S2):S198-S207. PMC: 4873917. DOI: 10.1017/S0022215116000633. View

19.

Madhoun M, Blankenship M, Blankenship D, Krempl G, Tierney W . Prophylactic PEG placement in head and neck cancer: how many feeding tubes are unused (and unnecessary)?. World J Gastroenterol. 2011; 17(8):1004-8. PMC: 3057142. DOI: 10.3748/wjg.v17.i8.1004. View

20.

Higginson I, Evans C . What is the evidence that palliative care teams improve outcomes for cancer patients and their families?. Cancer J. 2010; 16(5):423-35. DOI: 10.1097/PPO.0b013e3181f684e5. View